The Fly | AKTX

Unique Dual Inhibition Strategy: Nomacopan's dual mechanism of inhibiting both the C5 complement pathway and leukotriene B4 (LTB4) offers a distinct therapeutic approach, potentially providing broader anti-inflammatory and complement inhibition benefits compared to single-target therapies.

Addressing Unmet Needs in Refractory Cases: This dual mechanism positions Akari to potentially treat patients who are refractory or only partially responsive to existing C5 complement inhibitors, particularly in diseases like PNH, by targeting additional inflammatory pathways.

Versatile Therapeutic Potential Across Multiple Indications: Nomacopan is being investigated for a range of rare and severe inflammatory diseases including PNH, aHUS, and bullous pemphigoid, suggesting broad applicability where both complement and LTB4 play roles.

Clinical Development Risk: Failure to successfully complete clinical trials for its lead product candidate, nomacopan, or any other pipeline assets could prevent the company from obtaining regulatory approval and generating revenue.

Regulatory Approval Risk: Even if clinical trials are successful, Akari may not be able to obtain necessary regulatory approvals from health authorities like the FDA or EMA, which would prevent commercialization of its product candidates.

Financing and Liquidity Risk: Akari Therapeutics has a history of losses and requires substantial additional capital to fund its operations, ongoing clinical trials, and potential commercialization efforts, and there is no guarantee it will be able to raise such capital on favorable terms or at all.